Sionna Therapeutics, Inc. (SION) Stock Analysis
Healthcare · Biotechnology · NasdaqGM
Sionna Therapeutics, Inc. (SION) posted $0 in revenue for fiscal 2025, with a net loss of $75.27M, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on Sionna Therapeutics, Inc.
Sionna Therapeutics, Inc. has grown revenue from $0 to $0 over the last 4 fiscal years.
Synthesised from Sionna Therapeutics, Inc.'s SEC filings — descriptive, not advice. Ask the analyst your own question →
Sionna Therapeutics, Inc. revenue & earnings — last 4 fiscal years
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Gross profit | — | — | — | — |
| Net income | $-40.24M | $-47.26M | $-61.69M | $-75.27M |
| Net margin | — | — | — | — |
Source: Sionna Therapeutics, Inc. SEC filings (10-K).
Sionna Therapeutics, Inc.: no obvious red flags in the filings
Our deterministic scan of the filed statements — receivables vs sales, earnings vs cash, dilution, leverage and margins — didn't flag anything. Ask about the risks →
Explore 4 years of Sionna Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track SION in your portfolio →
Sionna Therapeutics, Inc. financial history by metric
About Sionna Therapeutics, Inc.
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Sionna Therapeutics, Inc. — frequently asked questions
What is Sionna Therapeutics, Inc.'s revenue?
Sionna Therapeutics, Inc. (SION) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Sionna Therapeutics, Inc. profitable?
No — SION reported a net loss of $-75.27M in fiscal 2025.
What is SION's P/E ratio?
Sionna Therapeutics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Sionna Therapeutics, Inc. have?
As of fiscal year 2025, SION carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Sionna Therapeutics, Inc.'s market cap?
Sionna Therapeutics, Inc. (SION) has a market capitalization of about $1.61B, based on the latest data in our nightly-refreshed cache.
When does Sionna Therapeutics, Inc.'s fiscal year end?
SION's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Sionna Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 4 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.